Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 13.71M shares rose 131.3% year over year, ahead of the +108.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 61.0% from the prior quarter. Over 3 fiscal years it compounded at +40.5% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +131.3% holds above the trailing-twelve-month pace of +108.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
13.71M+61.0% QoQ
Last fiscal yearDec 2025
8.51M+276.0% YoY
LTMMar 2026
9.62M+108.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+131.3%——
1 year+276.0%——
3-year CAGR+40.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
8.51M USD
Year-over-year change
+276.0%
4-year CAGR
+1008.9%

Weighted Avg Shares vs competitors

How TNXP compares with its peers on the latest reported figures

  • TNXP's LTM Mar 2026 weighted avg shares of 9.62M shares is the 9th highest of the 10 companies compared; the peer median is 85.54M shares.
  • Its year-over-year change of +108.1% is the 3rd highest of 10, against a peer median of +32.5%.
  • Over three fiscal years its annual growth of +40.5% compares with a peer median of +25.5%.
TNXP Competitors Peer median
Weighted Avg Shares for TNXP and competitors
Company Period LTM YoY 3-year CAGR
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+4.0%
FBRXForte Biosciences, Inc.LTM Mar 202688.77M +1552.7%+496.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +48.0%+78.9%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +130.2%+599.3%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 20269.62M +108.1%+40.5%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+17.9%
Peer median (excluding TNXP) 85.54M+32.5%+25.5%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.